Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the "**Company**") is pleased to announce that, in accordance with the Company Law of the People's Republic of China (the "**Company Law**"), the articles of association of the Company (the "**Articles of Association**") and other relevant provisions, the Company convened an employee representatives' meeting on June 5, 2026 (the "**Meeting**"), at which Mr. Li Shing Chung Gilbert ("**Mr. Li**") was elected as the employee representative Director of the fourth session of the Board.

Mr. Li is qualified to serve as the employee representative Director pursuant to the relevant provisions of the Company Law and the Articles of Association.

Pursuant to the Articles of Association, the election of Mr. Li as the employee representative Director is not subject to approval by the shareholders of the Company. Mr. Li will, together with the executive Directors, non-executive Directors and independent non-executive Directors elected at the general meeting of Shareholders, constitute the fourth session of the Board. His term of office shall commence on the establishment of the fourth session of the Board, following approval of appointments of other Directors of the fourth session of the Board on the date of the 2025 annual general meeting of the Company (i.e., June 12, 2026) and shall end on the expiry of the term of the fourth session of the Board. Mr. Li will not receive separate remuneration for his role as the employee representative Director. The amount of his remuneration and the basis for calculating it are determined according to the relevant remuneration policies of the Company. The Company will disclose his specific remuneration in the annual report in accordance with applicable requirements.

Following the election of the employee representative Director, the number of Directors who also serve as Senior Management and the number of employee representative Directors shall not exceed one half of the total number of Director, which complies with applicable laws, regulations and the provisions of the Company's articles of association.

The biographical details of Mr. Li are set out as follows:

Mr. LI Shing Chung Gilbert (李承宗), aged 47, is the chief financial officer, secretary of the Board and employee representative Director. He joined the Company in January 2008 as the financial controller and was appointed as the chief financial officer in January 2015. He was appointed as secretary of the Board in October 2016 and is primarily responsible for the overall financial function of the Company. In particular, he is responsible for the investment, financing and M&A activities of the Company. He was elected as an employee representative Director of the Company in December 2025 and has participated in the Company's major decision-making as a member of the Board. Mr. Li also serves as a supervisor or director at several subsidiaries of the Company.

Prior to joining the Company, Mr. Li had served at various roles in accounting and financial areas. From 2000 to 2003, he served as assistant manager of KPMG, a multinational financial audit, tax and advisory firm.

Mr. Li obtained his bachelor's degree in business administration from the Hong Kong University of Science and Technology in November 2000. Mr. Li obtained his master's degree in business administration from the China Europe International Business School (中歐國際工商學院) in July 2012. Mr. Li is a member of the Hong Kong Institute of Certified Public Accountants and the American Institute of Certified Public Accountants and a Chartered Financial Analyst.

Mr. Li serves as a director of Pharmaron Holdings Limited and other companies during the past five years. As at the date of this announcement, Mr. Li does not directly hold any interest in the shares of the Company but indirectly holds approximately 8,293,190 A shares of the Company through his minority interest in Pharmaron Holdings Limited. For the avoidance of doubt, Mr. Li does not control Pharmaron Holdings Limited. Save as disclosed above, Mr. Li has no relationship with any Directors, senior management or substantial shareholders of the Company. Mr. Li has not held any directorship in any other listed companies in the past three years.

Save as disclosed above, as at the date of this announcement, there is no other information relating to the election of Mr. Li that shall be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Company is not aware of any other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to extend its welcome to Mr. Li for his continued service on the Board.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
June 5, 2026

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Mr. Yu Jian and Prof. Tsang King Fung as independent non-executive Directors.